Current evidence suggests that controlling antibiotic resistance requires the monitoring of both susceptibility trends and antimicrobial usage within specific patient-care areas of the hospital. To assess the differences between antimicrobial usage-versus-susceptibility relationships found in the hospital and those relationships found in specific patient-care areas, susceptibility and antimicrobial usage data collected over a 5-year period (1992)(1993)(1994)(1995)(1996) at the Medical University of South Carolina were analyzed. For each area, the relationship between drug use and susceptibility was analyzed for 8 gram-negative organisms with respect to 19 different agents and for 3 staphylococci with respect to 10 agents with use of simple linear regression. The relationships found in the hospital had a poorer overall agreement with the relationships found in the intensive care units (ICUs; !20%) than they did with the relationships found in the non-ICUs (∼65%). Surveillance should include both susceptibility and drug usage patterns in individual areas within an institution.
A major issue confronting organized health care today is that of controlling the increase in antimicrobial resistance. Although multiple factors play a role in this problem, the selective pressures of inappropriate and widespread use of antibiotics are considered major contributors [1] [2] [3] . Several studies have reported higher rates of antimicrobial resistance among isolates from intensive care units (ICUs) than among isolates from general patient-care areas [4] [5] [6] [7] [8] [9] [10] . They also noted that using hospital-wide data to monitor susceptibility changes often obscures significant changes in specific patient-care areas.
Therefore, understanding the relationship between antibiotic use and increasing resistance and its association with individual patient-care areas has become one of the focal points in combating the development of resistant organisms. In fact, recent reports from the special task force of the American Society for Microbiology and from a joint committee comprising members of the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America advocate that individual hospitals monitor the relationship between antimicrobial use and resistance within specific patient-care areas [11, 12] .
Implementing these monitoring programs is only one part of the battle to prevent the progression of resistance. It is also important to understand the methods for analyzing the susceptibility and drug usage data once they have been collected. Most studies have examined the relationships between antimicrobial usage and susceptibility trends by analysis of only hospital-wide data [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . A few studies compared hospitalwide susceptibility trends with those trends within an ICU [4] [5] [6] [7] [8] [9] [10] . Of these studies, the majority did not compare the relationship between antimicrobial usage and susceptibility changes found in the hospital as a whole with those found in the individual patient-care areas. The few studies that did make these comparisons either used pooled data from multiple hospitals, which may mask relationships specific to individual hospitals, or did not attempt to use methods to correlate drug usage and susceptibility [4, 7, 9] . Thus the objective of this study was to statistically assess the agreement of hospital-wide antimicrobial usage-versus-susceptibility relationships to those of individual patient-care areas in a single institution.
Methods
The Medical University of South Carolina is a 600-bed tertiary care teaching hospital. Included in this study were the adult non-ICU areas and the following adult specialty patient-care areas/ICU: medical ICU, coronary care unit, neurosurgical ICU, cardiothoracic ICU, surgical/trauma ICU, burn unit, and oncology unit. Adult medical and surgical patients, including postoperative transplant recipients, are treated in the non-ICU areas. The latter include ∼400 beds. Census, antibiotic usage, and susceptibility data were collected on a quarterly basis from January 1992 through December 1996 and then were compiled into yearly data for subsequent analyses.
Census data. The total patient-days of hospitalization for the individual patient-care areas were obtained from the hospital Admissions Department. To account for the variation in census over time and among patient-care areas, the number of patient-days was used to normalize drug-usage data (grams of antibiotic/patientday) and the number of isolates per patient-day.
Antimicrobial usage data. Individual patient data for each antibiotic evaluated were electronically transferred from the hospital pharmacy computer system (Megasource, MSMEDS; Cerner, Kansas City, MO) to a spreadsheet (Excel; Microsoft, Redmond, WA) customized for this project. These data included patient name, location, drug order number, dose, dosing schedule, and the beginning and ending dates of therapy. Antibiotics included were ampicillin, ampicillin/sulbactam, ticarcillin, ticarcillin/clavulanate, piperacillin, penicillin, nafcillin, cefazolin, cefuroxime, ceftazidime, ceftizoxime, ceftriaxone, cefotaxime, amikacin, tobramycin, gentamicin, ciprofloxacin, ofloxacin, aztreonam, imipenem, trimethoprim-sulfamethoxazole (TMP-SMZ), erythromycin, clindamycin, tetracycline, and vancomycin. Penicillin and TMP-SMZ (dose based on TMP) doses were converted into milligrams with the use of standard conversions. No drug-usage data were available before 1993 for ofloxacin.
The transferred drug data were examined and adjusted before use in the data analysis as follows. First, drug orders were evaluated for duplicates, which were then removed from the database. Since we were most interested in assessing drug usage in treatment, rather than prophylactic regimens, we eliminated orders for 1-time doses, those with a duration of therapy !1 day, and preoperative doses. These orders comprised an average of 7.4% (range, 6.0%-8.7%) of the total drug-usage data. At quarterly intervals, data were screened for missing order dates. The number of missing days per quarter was calculated and then used to extrapolate the usage of all drugs for that quarter. For the entire 5-year period, 9% of the total number of days lacked drug-usage data.
With use of these data, the number of grams for each drug order was calculated from the dose, total number of daily doses, and days of antibiotic therapy. The days of antibiotic therapy were calculated by subtracting the beginning date from the ending date of therapy, and the dosing schedule was converted to the number of doses per day. The grams of each antibiotic were totaled for the adult hospital, the ICU, and the non-ICU areas and then were divided by the number of patient-days for the corresponding patient-care area. For example, in 1996, the medical ICU used 151 g of ampicillin, and the total number of medical ICU patient-days was 2032, which gave a value of 0.074 total g of ampicillin per medical ICU patient-day for 1996.
Susceptibility data. The total number of nonurine isolates and the number of susceptible nonurine isolates were collected individually from each adult ICU area and from the adult hospital as a whole. The non-ICU data were calculated by subtraction of the data from the total ICU areas from the hospital-wide data. Only data from hospitalized inpatients were included in the analysis.
Susceptibility data were obtained for the following organisms isolated from hospitalized adult inpatients: Acinetobacter anitratus (baumannii), Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens, coagulase-negative Staphylococcus, methicillin-susceptible Staphylococcus aureus, and methicillin-resistant S. aureus. Susceptibility testing of these isolates by means of the Vitek automated susceptibility system (bioMeriéux Vitek, Hazelwood, MO) was performed by the Department of Clinical Microbiology. The susceptibility breakpoints used by the system were in accordance with guidelines of the National Committee for Clinical Laboratory Standards during the study period. Neither the susceptibility testing methods nor the susceptibility breakpoints changed during the study period.
In our institution, data from the Vitek system are electronically transferred to the Cerner laboratory management software on the hospital mainframe computer. This program removes duplicate isolates before creating antibiograms for each patient-care area.
For each organism, the percent susceptible (%S) was calculated by dividing the number of susceptible isolates by the total number of isolates and multiplying by 100. Only those isolates with for any year during the study period were considered %S у 70% of clinical importance and were included in the analysis. This criterion was chosen because it probably represents a range of %S that is clinically relevant in decision-making about empirical antimicrobial therapy in our institution.
Data analysis. Comparisons were made between the non-ICU and ICU areas as a group with respect to the number of isolates per patient-day, with use of the Student's t test. The days of antibiotic therapy and %S over the 5-year study period were assessed by means of simple linear regression to characterize overall trends. In addition, an analysis was performed of days of antibiotic therapy and susceptibility for which there was a continual change in the same direction (i.e., increase or decrease) for every year. This is subsequently referred to as the trend analysis. In the trend analysis, with use of the slope of the regression line of susceptibility over time, the %S was calculated with the regression equation for 1992 and 1996. Then the percentage change (increase or decrease) was calculated by subtracting the 1992 data from the 1996 data, dividing by the 1992 data, and multiplying by 100. This same type of calculation was performed to evaluate trends in drug usage.
The relationship between antimicrobial usage (grams per patientday) and %S was assessed with simple linear regression. For every patient-care area, the usage of each agent was analyzed against each organism's susceptibility to the drug (e.g., with use of data from the medical ICU, susceptibility of S. marcescens to ciprofloxacin versus ciprofloxacin [grams per patient-day]). Nineteen agents (ampicillin, ampicillin/sulbactam, ticarcillin, ticarcillin/clavulanate, piperacillin, cefazolin, cefuroxime, ceftazidime, ceftizoxime, ceftriaxone, cefotaxime, amikacin, tobramycin, gentamicin, ciprofloxacin, ofloxacin, aztreonam, imipenem, and TMP-SMZ) were analyzed against the 8 gram-negative organisms, and 10 agents (ampicillin, ampicillin/sulbactam, penicillin, nafcillin, cefazolin, TMP-SMZ, erythromycin, clindamycin, tetracycline, and vancomycin) were analyzed against the 3 staphylococci.
Within the hospital or within an individual patient-care area, the number of possible relationships between antimicrobial usage and susceptibility was determined by the number of antimicrobial agents and organisms evaluated. There were 152 possible antimicrobial usage-versus-susceptibility relationships for the gram-negative bacilli and 30 possible relationships for the staphylococci. Of these relationships, only those determined from the linear regression analysis to have a coefficient of determination (r 2 ) of at least 0.5 were further evaluated. Therefore, only those drug/organism combinations in which %S was у70% in any year and the r 2 from the drug usage-versus-susceptibility regression analysis was у0.5 were included in this analysis. Then these drug usage-versus-susceptibility relationships found in the hospital were compared with those found in the ICU areas and also with those found in the non-ICU areas.
These comparisons were divided into 3 categories: (1) agreement, (2) disagreement, and (3) no comparison possible. There was agreement when a relationship was found in the hospital and in a specific patient-care area; this required the slope of the regression line to have the same sign (e.g., both having a negative slope). There was disagreement when slopes for the regression lines had opposing signs (e.g., a positive slope in the hospital versus a negative slope in an individual ICU area). No comparison could be made between the hospital and a specific patient-care area when a relationship was not found in either area or in only one area as a result of our inclusion criteria. Percentages of agreement, disagreement, and no comparison were calculated on the basis of the total number of antimicrobial usage-versus-susceptibility relationships for all the drug/organism combinations found in the hospital and the number of relationships found in each patient-care area (e.g., 30 relationships were found in the hospital, and the medical ICU had 7 relationships that agreed, resulting in a 23% [7/30] agreement between the hospital and the medical ICU).
Results
The percentage of hospital patient-days attributed to the individual patient-care areas was relatively consistent over the 5-year study period from 1992 through 1996 (table 1) . The non-ICU patient-days comprised the major percentage of hospital patient-days.
The percentage of total days of antibiotic therapy contributed by each of the individual drug classes is shown in table 2. The patterns of antibiotic use in the non-ICU areas were similar to those in the hospital; however, there was considerable variability within the ICU areas. Overall, cephalosporins were the most frequently used agents in our institution. Drug usage in the ICU areas comprised ∼25% of the total hospital days of antibiotic therapy but ∼20% of patient-days. Overall, the days of antibiotic therapy and total grams per patient-day of antibiotic use in the ICU areas were 1.5 times those of the non-ICU. Table 3 lists the 8 antibiotics for which a continual increase or decrease in drug use (days of therapy) was observed from 1992 through 1996. The antibiotic-usage trends were similar for the hospital and the non-ICU, which is not surprising since the non-ICU accounts for the largest number of patient-days of any patient-care area. Oncology was the ICU area in which an increase in antibiotic usage was most often observed. Aztreonam usage declined dramatically from 1992 to 1996; this decline was seen in multiple patient-care areas.
The percentages of gram-negative organisms and staphylococci isolated in the hospital as a whole and within each patientcare area are displayed in tables 4 and 5, respectively. P. aeru- Figure 1 . For the gram-negative organisms, percentage of agreement (white bars) or disagreement (black bars) between antimicrobial usage (grams per patient-day)-versus-susceptibility relationships found in the hospital and the same relationships found in specific patientcare areas. Percentages do not total 100% because some relationships found in the hospital were not found in each patient-care area, owing to the inclusion criteria. Burn, burn unit; CCU, critical care unit; CTICU, cardiothoracic ICU; MICU, medical ICU; non-ICU, non-ICU areas; NSICU, neurosurgical ICU; Onc, oncology unit; STICU, surgical/trauma ICU. ginosa was the most common gram-negative organism isolated in the hospital and within the non-ICU and 4 of the 7 ICU areas. Together, methicillin-susceptible S. aureus and coagulasenegative Staphylococcus accounted for the majority (∼90%) of the staphylococci isolated in the hospital; similar findings were noted within the non-ICU and the ICU areas. Organisms isolated from the non-ICU comprised ∼75% of both the gramnegative organisms and staphylococci that were evaluated. However, when normalized for patient-days, the number of ICU isolates was 1.5 and 1.3 times that of the non-ICU isolates of gram-negative organisms and staphylococci, respectively. For K. pneumoniae, E. cloacae, P. mirabilis, E. aerogenes, coagulase-negative Staphylococcus, and methicillin-resistant S. aureus, the number of isolates/patient-day in the ICUs as a group was significantly greater than in the non-ICU ( ). P ! .05 Trends in susceptibility patterns over the 5-year period occurred in different drug/organism combinations in the hospital than in individual ICU or non-ICU areas (table 6). The only exception was for the E. aerogenes/ceftriaxone combination, in which a continual decrease in susceptibility over the study period was noted for the hospital and the non-ICU. A. baumannii had a continual decrease in %S to more antibiotics than was noted for any other organism.
For the gram-negative organisms, 30 drug usage-versussusceptibility relationships for the adult hospital met our inclusion criteria. Of these relationships, those for the non-ICU areas had the greatest percentage of agreement (∼63%) with the relationships for the hospital ( figure 1) . Overall, the ICU areas had !20% agreement with the hospital. Disagreement was observed between the relationships found in the hospital and those found in 4 of the 7 ICU areas, with the greatest percentage of disagreement occurring between the hospital and the neurosurgical ICU. Eighty percent of the time there were no relationships found in the ICU areas to compare with the relationships in the hospital. The inverse of this was also found, that is, where drug usage-versus-susceptibility relationships meeting our criteria were found in patient-care areas (ICU or non-ICU areas) and not hospital-wide.
Ampicillin/sulbactam, ticarcillin/clavulanate, ciprofloxacin, and ofloxacin were the agents most often associated with relationships where agreement occurred between the hospital and the patient-care areas, whereas ceftazidime was observed to be associated only with disagreement. This disagreement occurred with A. baumannii between the hospital (negative slope) and the neurosurgical ICU (positive slope). With ticarcillin, none Percentages do not total 100% because some relationships found in the hospital were not found in each patient-care area, owing to the inclusion criteria. Burn, burn unit; CCU, critical care unit; CTICU, cardiothoracic ICU; MICU, medical ICU; non-ICU, non-ICU areas; NSICU, neurosurgical ICU; Onc, oncology unit; STICU, surgical/trauma ICU) of the patient-care areas had relationships that could be compared with the relationships found in the hospital. S. marcescens, A. baumannii, and E. coli were the gram-negative organisms most frequently associated with relationships where agreement occurred between the hospital and the patient-care areas. P. aeruginosa was the only organism that was not associated with disagreement between the hospital and the patient-care areas. No relationships for E. cloacae met our criteria with the hospital-wide data. There were 7 hospital drug usage-versus-susceptibility relationships meeting our criteria for staphylococci. The greatest percentage of agreement occurred between the hospital and the non-ICU ( figure 2) . Overall, the agreement between the hospital and individual ICU areas averaged !15%. Although disagreements occurred between the relationships noted in the hospital and only 2 of the ICU areas, an average of 85% of the time no relationships were observed in the ICU areas to compare with those of the hospital. Ampicillin/sulbactam and nafcillin were the agents most often associated with relationships where agreement occurred between the hospital and the patient-care areas; however, they were also the only agents that were associated with disagreement. With vancomycin, none of the patient-care areas had relationships that could be compared with the relationships found in the hospital.
Of the staphylococci, methicillin-susceptible S. aureus was the organism most often associated with relationships where agreement occurred between the hospital and the patient-care areas, but it was also the only one of the staphylococci associated with disagreement. No comparison could be made with methicillin-resistant S. aureus since no relationships were found in the patient-care areas to compare with the relationships observed in the hospital.
Discussion
Hospital-wide surveillance has traditionally been used for the detection of resistance problems within an institution. However, sole reliance on hospital-wide surveillance data may be misleading, since these data can mask important trends in resistance within individual patient-care areas [5-7, 9, 25-28] . This is not surprising, given the variability in patient populations and severity of illness, antimicrobial use, and infection-control practices within a given institution. Recently, recommendations have been made suggesting that individual patient-care areas should be monitored separately in an attempt to assess antimicrobial resistance [7, 11, 12, 26] . In this study, we incorporated the monitoring of both drug usage and susceptibility and then compared the drug use-versus-susceptibility relationships found in the hospital with those found in the individual patientcare areas. The importance of monitoring individual patient-care areas, especially ICU, was underscored by the recent findings from Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology), in which the percentage of antimicrobial-resistant isolates was significantly higher among the ICU patients than among the non-ICU inpatients [4, 5, 25, 27] . In this study, 8 hospitals were selected to represent different geographic locations, as well as different hospital sizes and teaching affiliations. Data were collected for certain antibiotic/pathogen combinations and then were stratified for each ICU and for non-ICU areas. The findings of higher percentages of antimicrobial-resistance isolates among the ICU patients was the same whether these data were analyzed for each hospital individually or for all of the hospitals grouped together [5] .
In a 4-year microbiological surveillance study of a single university hospital, Stratton et al. [7, 9] investigated the recovery rate of clinical isolates and their susceptibility patterns in the ICU and the entire hospital. Their reports concerning the hospital-wide data indicated no major resistance problems; however, evaluation of the ICU-specific data revealed a serious resistance problem with P. aeruginosa. In another study, at a 700-bed tertiary adult-care medical center, investigators noted striking differences between hospital-wide and ICU antibiograms for P. aeruginosa [6] .
These studies differ from our study in that they did not examine the relationships between antimicrobial usage and susceptibility. However, they do illustrate that evaluation of hospital-wide susceptibility data can mask the occurrence of severe resistance problems and the variability seen over time in pathogen prevalence rates within an ICU. These findings, like ours, illustrate some of the problems that can occur with use of only hospital-wide susceptibility data.
Although a causal relationship between antibiotic use and resistance patterns is difficult to prove, several studies have shown a decrease in antimicrobial resistance after the implementation of antibiotic control measures. A recent study in Finland revealed a decline in the occurrence of erythromycin resistance in group A streptococci when macrolide use was reduced [13] . Stratton et al. [7] used the findings from surveillance of unit-specific resistance patterns to make modifications in antibiotic usage. After these modifications, the percentage of P. aeruginosa isolates resistant to imipenem and several other antipseudomonal b-lactams decreased.
A 10-year study of aminoglycoside use in a 700-bed institution revealed changes in patterns of resistance to gentamicin and tobramycin. With the introduction of amikacin, use of gentamicin and tobramycin declined, and this decline was followed by a reduction in resistance of gram-negative bacilli to these agents. When gentamicin was reintroduced, an increase in resistance to gentamicin and tobramycin was observed [18] . The emergence of multidrug-resistant E. cloacae at 1 institution prompted the restriction of ceftazidime use. Over the subsequent 1-year period, susceptibility to ceftazidime increased from 54% to 75% [29] . These studies concur with our findings, which support the link between antimicrobial usage and changes in susceptibility.
ICUs have a higher prevalence of resistant isolates and greater antibiotic use than do non-ICU. Hospital-wide microbiologic surveillance studies can mask important resistance patterns that can be found with unit-specific surveillance. Controlling antibiotic usage in many cases has improved susceptibility patterns. It seems logical that monitoring these areas and correlating their antibiotic use to resistance patterns specific for these areas is an appropriate course of action in order to assess and then implement new antibiotic policies that could reduce resistance.
Currently, most hospitals perform surveillance studies by tracking the percentage of susceptible isolates on the basis of hospital-wide data. When a problem is noted for a particular drug/organism combination, an examination of that antibiotic's usage is typically initiated. When a relationship is observed between drug usage and susceptibility, then some type of intervention, such as antibiotic restriction, may be implemented. patient-care areas. Moreover, clinically important susceptibility trends and relationships with antimicrobial usage within specific patient-care areas of the hospital will likely be "diluted" by hospital-wide results. Our study confirms previous observations that susceptibility trends vary between hospital-wide and individual patient-care units. Furthermore, we demonstrated that drug usage-versus-susceptibility relationships may also vary. Thus, before antibiotic restriction policies based on hospitalwide surveillance data are implemented in an individual patientcare area, a review of that area is warranted. Otherwise, incorrect assumptions concerning the relationship between drug use and resistance based on hospital-wide results may lead to inappropriate allocation of both financial and personnel resources. In addition, antimicrobial agents may be restricted unnecessarily in a specific patient-care area, which might deny appropriate therapy to patients with life-threatening infections.
